A systematic review of phage therapy applied to bone and joint infections: an analysis of success rates, treatment modalities and safety

Abstract

Bone and joint infections are difficult to treat, and increasing antibiotic resistance has only made them more challenging. This has led to renewed interest in phage therapy (PT). The aim of this systematic review was to determine success rate, current treatment modalities and safety of PT in bone and joint infections. A systematic search of PubMed, EMBASE and Cochrane databases as well as the journal PHAGE for literature published between January 2000 and April 2021 was conducted according to PRISMA guidelines to identify all human studies assessing bacteriophages as therapy for bone and joint infections. All study designs and patient populations were eligible. The review’s primary outcome was success rate. Twenty records describing a total of 51 patients and 52 treatment episodes were included. No randomized controlled studies were identified. The overall success rate was 71% (n = 37/52). Topical administration alone was the most frequent administration route (85%, n = 44/52). Antibiotics were administered concomitantly with PT in the majority of treatments (79%, n = 41/52), and surgery was performed for 87% (n = 45/52) of treatment episodes. Four minor adverse events related to PT were reported, representing 8% (n = 4/52) of treatment episodes. PT for bone and joint infections has not been evaluated in any randomized controlled clinical study, and current administration modalities are highly variable between case reports and case series. While publications included here show potential benefit and few adverse effects, clinical trials are warranted to assess the efficacy of PT for bone and joint infections and determine optimal treatment modalities. Cite this article: EFORT Open Rev 2021;6:1148-1156. DOI: 10.1302/2058-5241.6.210073

Bacteriophage Therapy for Staphylococcus Aureus Infections: A Review of Animal Models, Treatments, and Clinical Trials

“…There are a few animal studies on bacteriophage treatment for bone and joint infections, but most were conducted in murine models (Genevière et al, 2021;Gibb and Hadjiargyrou, 2021). As detailed in the case reports sections, implant-related staphylococcal infections resistant to most antibiotics represent a serious problem in orthopedic surgery.…”

“…However, there are limited therapeutic alternatives in treatment failure, and amputation is relatively frequent. S. aureus (33 to 43%), Staphylococcus epidermidis (18 to 40%), and Enterococcus species (2.5 to 15%) are the most prevalent causes of these infections (Genevière et al, 2021;Gibb and Hadjiargyrou, 2021).…”

Mini Review Therapeutic Strategies Targeting for Biofilm and Bone Infections

“…In some cases, phages can incorporate their genome into the host genome as a prophage and reenter the lytic cycle under environmental stressors ( Doss et al, 2017 ). This property seems to endow phages with the ability to kill persister cells in biofilms with low metabolic states, as prophages can lyse these cells when metabolic activity is recovered ( Geneviere et al, 2021 ). This mechanism is illustrated in Figure 3 with a red background.…”

The Microbiome in Pancreatic Cancer-Implications for Diagnosis and Precision Bacteriophage Therapy for This Low Survival Disease

“…Bacteriophages are viral predators of bacteria, whose actions are almost exclusively specific for their target host species ( Clokie et al., 2011 ; Batinovic et al., 2019 ). There have been extensive reports and reviews on the application of bacteriophages in clinical scenarios ( Genevière et al., 2021 , Liu et al., 2021b , Pirnay et al., 2022 ; Satta et al., 2022 ). More recently, bacteriophage therapy has been successfully applied in human clinical trials, and on compassionate grounds for critically ill patients with resistant and difficult to treat infections, in Western countries ( Vandenheuvel et al., 2015 ; Schooley et al., 2017 ; Dedrick et al., 2019 ; Maddocks et al., 2019 ).…”